(PRLeap.com) Aachen, Germany, 09 January 2025 - Grรผnenthal announced today that Prof. Dr. Uli Brรถdl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brรถdl has more than 15 years of industry experience. He joins Grรผnenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brรถdl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.
Uli Brรถdl graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig-Maximilians University Munich.
"The unique focus on improving the quality of life of underserved patients suffering from pain attracted me to Grรผnenthal," says Uli Brรถdl. "I look forward to joining the team and further driving Grรผnenthal's innovation pipeline."
"With Uli, we have been able to attract an excellent leader," says Gabriel Baertschi, CEO of Grรผnenthal. "His extensive experience in R&D and commercial functions combined with Uli's drive to bring innovative medicines to patients will help us propel our vision of a world free of pain."
About Grรผnenthal
Grรผnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grรผnenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grรผnenthal employed around 4,400 people and achieved revenues of ๏ฟฝ1.8 billion.
More information: https://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
For further information, please contact:
Florian Dieckmann, Head Global Corporate Affairs & Communication
Tel.: +49 241 569-2555
Florian.Dieckmann@grunenthal.com
GET IN TOUCH
Florian Dieckmann
Grรผnenthal Group
+49 241 569-2555
https://www.grunenthal.com
You can see the original version and more on PRLeap here: http://www.prleap.com/pr/302201/grunenthal-appoints-prof-dr-uli-brodl-as-chief-scientific-officer
